PATENT CLAIM ANALYSIS

Application Number: 16283926
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-10
Patent Classification: ["514", "221000"]

Abstract:
Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

Claim (Index 30):
A method of modulating an activity of a GABAA receptor in a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein said compound is or and\n wherein said subject has one or more syndromes selected from the group consisting of: Childhood absence epilepsy (CEA), Juvenile absence epilepsy, Juvenile myoclonic epilepsy (JME), West syndrome, Dravet syndrome, and Lennox-Gastaut syndrome (LGS).

Metadata:
- Claim Count in Document: 56.0
- Percentile: 99.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15560002', '13458168', '14637334', '11383624', '10333151']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.753391397482439
- 35 USC 102 Novelty (BERT): 0.5984208240542689
- Combined Prediction Score: 0.737894340139622
- Mean Citation Score: 382.309016
- Max Citation Score: 619.8617
- Similarity Product: 406.78076764117486

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test